Introduction {#sec1}
============

Oral cancer is a major cause of morbidity and mortality worldwide with a low response to chemotherapy and to most standard anticancer drugs. Resistance to the process of regulated cell death is a decisive factor in the carcinogenesis of oral neoplastic lesions and has been held responsible for tumor recurrence as well as chemo- and radiotherapy resistance \[[@cit0001], [@cit0002]\]. Overcoming the resistance is therefore a major challenge to treat oral neoplastic lesions. This has led to an increased effort to identify effective agents that might help in achieving a better response and hence reducing the burden of oral cancer. One such agent is vitamin D, which has been shown to have antiproliferative, anti-invasive properties, and induces apoptosis in a number of tumor cell types including oral squamous cell cancer as well as oral precancerous lesions \[[@cit0003]--[@cit0007]\]. It is also hypothesized that vitamin D increases the effectiveness of cytotoxic chemotherapy of oral cancer \[[@cit0008]\].

Palliative care is directed towards minimizing symptoms of adjuvant therapy, relieving suffering and thereby improving the quality of life (QOL). The high frequency of vitamin D deficiency in cancer patients \[[@cit0009], [@cit0010]\], the effect of normal vitamin D status on bodily functions \[[@cit0011]\], mandates efforts to explore its role in oral neoplasms. Since the discovery of an autocrine-paracrine role of local synthesis and signaling of vitamin D in multiple target tissues including prostate, breast and colon \[[@cit0012], [@cit0013]\], studying VDR and corresponding serum vitamin D levels seems to be reasonable for guiding supportive treatment of patients with premalignant lesions and oral cancer.

Material and methods {#sec2}
====================

It was a prospective observational study conducted in the Department of General Surgery, King George's Medical University Lucknow in collaboration with the Department of Pathology, Ram Manohar Lohia Institute Medical Sciences Lucknow from August 2012 to August 2013 after institutional ethical committee approval (Reference Code: 57 ECM II-B/P11). 110 patients with oral neoplastic lesions (23 oral premalignant lesions (15 diagnosed as "leukoplakia without dysplasia"; 8 diagnosed as "leukoplakia with mild dysplasia"), and 87 cases of invasive oral squamous cell carcinoma) were included in this study and served as "cases". 95 normal healthy, age- and sex-matched individuals unrelated to the patients were recruited to serve as "controls". The mean age of cases was 42.67 ±10.83 years as compared to controls 48.45 ±13.48 years (*p* = 0.12).

Written informed consent was taken from both cases and controls prior to enrollment. Clinical and pathological data were entered into a pre-structured proforma, which included demographic profile, subsite of the tumor, TNM staging of the tumor (based on AJCC 7^th^ edition 2010) and histological grading. The clinical characteristics of the patients with invasive oral squamous cell carcinoma are detailed in [Table 1](#t0001){ref-type="table"}. Punch biopsy specimens were subjected to histopathological and VDR evaluation. Five milliliters of blood sample was collected through peripheral venous puncture from each case and control for serum vitamin D level (25-hydroxy vitamin D) estimation (using the chemiluminescent immunoassay method).

###### 

Clinicopathological characteristics of patients with oral squamous cell carcinoma

  Characteristics                                                     No. of malignant cases(*n* = 87)   No. of malignantcases(%)
  ------------------------------------------------------------------- ---------------------------------- --------------------------
  Sex                                                                                                    
  Female                                                              18                                 20.7
  Male                                                                69                                 79.3
  Subsite                                                                                                
  Alveolus                                                            09                                 
  Floor of mouth                                                      02                                 
  Buccal mucosa (GB sulcus, cheek, etc.)                              54                                 
  Lip                                                                 03                                 
  Tongue                                                              16                                 
  Retromolar trigone                                                  03                                 
  Primary tumor (T)[\*](#tf1-1){ref-type="table-fn"}                                                     
  T1                                                                  02                                 
  T2                                                                  20                                 
  T3                                                                  13                                 
  T4A                                                                 09                                 
  T4B                                                                 43                                 
  Regional lymph nodes (N)[\*](#tf1-1){ref-type="table-fn"}                                              
  N0                                                                  25                                 40.2
  N1                                                                  41                                 47.1
  N2                                                                  20                                 11.5
  N3                                                                  01                                 1.1
  Histological grade (G)[\*](#tf1-1){ref-type="table-fn"}                                                
  G1                                                                  38                                 43.7
  G2                                                                  28                                 32.2
  Gx[\*\*](#tf1-2){ref-type="table-fn"}                               21                                 24.1
  Anatomic stage/prognostic groups[\*](#tf1-1){ref-type="table-fn"}                                      
  II                                                                  02                                 2.3
  III                                                                 15                                 17.2
  IVA                                                                 26                                 29.9
  IVB                                                                 44                                 50.6

According to AJCC 7^th^ Edition 2010

Grade could not be assessed

Technique of VDR estimation {#sec2.1}
---------------------------

Slides were fixed overnight at 60 degrees Celsius, dewaxed in xylene, and rehydrated in graded alcohol series. These slides were blocked in H~2~O~2~ methanol and subjected to antigen retrieval. They were incubated with a respective primary antibody (Mouse monoclonal in 1 : 200 dilutions, Abcam, USA, Cat no. ab110106) for an hour and were treated with secondary antibody (Dakopatts, Germany, Cat no. K500711). The sections were incubated with DAB (3,3'-diaminobenzidine tetrahydrochloride) and were counterstained with hematoxylin, which gave a blue color and was thereafter mounted with DPX.

Slides were examined under a microscope and a minimum of 500 malignant cells counted. Brown stained cells were suggestive of VDR staining ([Fig. 1](#f0001){ref-type="fig"}). The number of positively stained cells were counted and recorded as follows: score 0 for nil, score 1 for 1--10%, score 2 for 11--50%, score 3 for 51--80%. For intensity, a score of 1, 2 and 3 was given for weak, moderate and strong staining respectively. The immunoreactivity score (IRS) was assigned based on the work of Remmele and Stegner \[[@cit0014]\]. It was calculated as a product of the staining score and intensity score \[score 1 × score 2\]. Slides were considered negative (IRS 0--1), moderately positive (IRS 2--4) or highly positive (IRS 6--12).

![Vitamin D receptor immunohistochemistry in **A)** Adjacent epithelium, **B)** Transition zone and **C)** Oral squamous cell carcinoma showing an increasing trend in the nuclear expression of vitamin D receptor from A to C (DAB × 200 × digital magnification)](WO-21-30175-g001){#f0001}

Vitamin D score estimation {#sec2.2}
--------------------------

Serum vitamin D levels were estimated in blood and each subject was allocated a score taking vitamin D sufficient levels \[[@cit0015]\] to be the reference base value ([Table 2](#t0002){ref-type="table"}).

###### 

Vitamin D score

  Status (levels of vitamin D)                 Vitamin D score
  -------------------------------------------- -----------------
  Vitamin D sufficient (30--100 ng/ml)         0
  Vitamin D insufficient (21--29 ng/ml)        --1
  Vitamin D deficient mild (12--20 ng/ml)      --2
  Vitamin D deficient moderate (6--11 ng/ml)   --3
  Vitamin D deficient severe (˂ 6 ng/ml)       --4

Vitamin D supplementation in advanced oral cancer {#sec2.3}
-------------------------------------------------

To assess the effect of vitamin D supplementation on quality of life in advanced oral cancer patients, the inoperable/unresectable cases (*n* = 45) were categorized into two groups: Group I (without supplementation, *n* = 21) and Group II (with supplementation, *n* = 24). All patients (*n* = 45) were given concurrent chemoradiation (46 Gray in 23 fractions at 200 cGy/fraction/week with cisplatin). In the supplemented group, vitamin D was given in a dose of 1000 IU BD per day \[[@cit0016]\] for 3 months. Patients were followed up and assessed for change in the quality of life. QOL was assessed on three different scales: the oral mucositis scale (OMS) \[[@cit0017]\], the swallowing performance status scale (SPSS), and a QOL-based four-point Likert-type categorical scale. \[[@cit0018]\] OMS parameters included erythema, atrophy, hyperkeratosis, lichenoid changes, edema, ulceration, pseudomembrane, xerostomia and pain. SPSS included difficulty in swallowing from grade 1 to 7 in increasing order of severity. The QOL-based categorical scale included swallowing difficulties, mouth pain, throat pain, chewing difficulties, hoarse voice, sticky saliva, dry mouth, taste difficulties and skin alterations based on a four-point Likert-type questionnaire.

Statistical analysis {#sec2.4}
--------------------

Data were summarized as mean ± SD. Two independent groups were compared by independent Student's t-test. Two independent groups were also compared by the nonparametric Mann-Whitney U test. Groups were also compared by nonparametric Kruskal-Wallis (H) analysis of variance (ANOVA) by ranks and the significance of differences between the groups was determined by the Z test. Two dependent groups were compared by the Wilcoxon (W) matched pairs test. Discrete (categorical) groups were compared by the χ2 test. A two-sided (α = 2) p \< 0.05 was considered statistically significant. All analyses were performed on STATISTICA software (Windows version 6.0).

Results {#sec3}
=======

Vitamin D scores {#sec3.1}
----------------

Vitamin D deficiency was widely prevalent among cases (84/110; 76.3%) as well as healthy controls (65/95; 68.4%). The mean (± SD) vitamin D score of cases (--1.90 ±0.43; range --3 to 0) was significantly lower compared to controls (--1.33 ±0.62, range --2 to 0) (p = 0.002).

VDR expression {#sec3.2}
--------------

The mean percentage of cells stained was significantly lower in cases as compared to controls (1.93 ±0.59 vs. 1.21 ±1.12, *p* = 0.013). The mean intensity and IRS were found to be higher in cases compared to controls but the difference was not statistically significant ([Table 3](#t0003){ref-type="table"}). IRS significantly decreased with progressing anatomic stages mentioned in AJCC staging (stage II -- 4.50 ±2.12; stage III -- 4.33 ±3.37; stage IVA -- 3.15 ±2.66 and stage IVB -- 1.27 ±2.07; *p* \< 0.001).

###### 

Vitamin D receptor expression in cases and controls

  Parameters(mean ± SD)   Cases(*n* = 110)   Controls(*n* = 95)   p-value
  ----------------------- ------------------ -------------------- ---------
  \% cells stained        1.21 ±1.12         1.93 ±0.59           0.013
  Intensity               1.23 ±1.14         1.13 ±0.92           0.824
  IRS                     2.44 ±2.77         2.33 ±1.84           0.680

Vitamin D supplementation in advanced oral cancer {#sec3.3}
-------------------------------------------------

### Changes in vitamin D scores {#s3c1}

All patients with advanced oral cancer were deficient in vitamin D scores (range --3 to --1). Vitamin D scores of the two groups are summarized in [Table 4](#t0004){ref-type="table"}. The mean vitamin D scores of the two groups at pre-supplementation were found to be similar; however, after supplementation, the scores in the supplemented group differed significantly from those in the non-supplemented group (*p* = 0.013). Both groups showed a significant improvement in vitamin D scores after 3 months, and the change in the supplementation group was significantly higher (41.4%) as compared to the group without supplementation (*p* = 0.03; [Table 4](#t0004){ref-type="table"}).

###### 

Vitamin D scores of two groups before and after vitamin D supplementation

  Groups                                        Pre-supplementation values(mean ± SD)   Post-supplementation values(mean ± SD)   Change in vitamin D score(mean ± SD)   *p*-value
  --------------------------------------------- --------------------------------------- ---------------------------------------- -------------------------------------- -----------
  Group I (*n* = 21; without supplementation)   --1.86 ±0.36                            --0.94 ±0.80                             0.89 ±0.90                             0.002
  Group II (*n* = 24; with supplementation)     --1.75 ±0.53                            --0.29 ±0.46                             1.52 ±0.51                             \< 0.001
  *p*-value                                     0.678                                   0.013                                    0.032                                  \-

Quality of life in advanced oral cancer ([Table 5](#t0005){ref-type="table"}) {#sec3.4}
-----------------------------------------------------------------------------

### Oral mucositis scale {#s3d1}

Vitamin D supplementation significantly improved erythema, lichenoid, edema, ulceration and pain in patients with inoperable/unresectable oral cancer.

###### 

Quality of life scores of two groups with advanced oral cancer

  Oral mucositis scaleindividual parameters          Group I (*n* = 21)(without vitamin D supplementation)   Group II (*n* = 24)(with vitamin D supplementation)   Change in values   *P*-value                                  
  -------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- ------------------ ------------ -------------- -------------- ----------
  Erythema                                           1.71 ±0.46                                              1.48 ±0.68                                            2.08 ±0.72         0.79 ±0.72   0.24 ±0.44     1.29 ±0.62     \< 0.001
  Atrophy                                            0.43 ±0.51                                              0.29 ±0.46                                            0.29 ±0.46         0.08 ±0.28   0.14 ±0.36     0.21 ±0.41     0.577
  Hyperkeratosis                                     0.00                                                    0.00                                                  0.17 ±0.38         0.04 ±0.20   0.00           0.13 ±0.34     0.098
  Lichenoid                                          0.00                                                    0.19 ±0.40                                            0.17 ±0.38         0.08 ±0.28   --0.19 ±0.40   0.08 ±0.41     0.029
  Edema                                              1.57 ±0.51                                              1.29 ±0.72                                            1.46 ±0.51         0.50 ±0.59   0.29 ±0.46     0.96 ± 0.55    \< 0.001
  Ulceration                                         0.52 ±0.51                                              0.86 ±0.85                                            0.71 ±0.69         0.25 ±0.44   --0.33 ±0.48   0.46 ± 0.59    \< 0.001
  Pseudo membrane                                    0.00                                                    0.00                                                  0.00               0.00         0.00           0.00           --
  Xerostomia                                         0.43 ±0.51                                              0.95 ±0.74                                            0.42 ±0.50         0.63 ±0.65   --0.52 ±0.68   --0.21 ±0.72   0.140
  Pain                                               1.62 ±0.67                                              1.24 ±0.89                                            1.17 ±0.48         0.29 ±0.55   0.38 ±0.50     0.88 ±0.61     0.005
  **SPSS (score)**                                   4.43 ±0.51                                              4.48 ±0.68                                            5.33 ±0.70         4.63 ±0.77   --0.05 ±0.67   0.71 ±0.46     \< 0.001
  **QOL 4-point Likert categorical scale (score)**   8.76 ±0.77                                              8.62 ±0.74                                            9.58 ±0.58         7.50 ±1.41   0.14 ±0.57     2.08 ±1.28     \< 0.001

P-value denotes statistical significance of change from pre- to post-supplementation in group I vs. group IIww

### Swallowing performance status scale (SPSS) {#s3d2}

Vitamin D supplementation significantly improved the SPSS scores with improvement in swallowing performance status after three months (*p* \< 0.001).

### QOL-based four-point Likert-type categorical scale {#s3d3}

Vitamin D supplementation significantly (*p* \< 0.001) improved the four-point QOL-based Likert-type categorical scale scores over the three-month period.

Discussion {#sec4}
==========

Vitamin D and its metabolites reduce the incidence of various cancers by inhibiting tumor angiogenesis, stimulating mutual adherence of cells, and enhancing intercellular communication, thereby strengthening the inhibition of cellular proliferation \[[@cit0019]\]. A low serum level of 25-hydroxy vitamin D, the principal form of circulating vitamin D, is the main marker of vitamin D deficiency \[[@cit0020]\]. Large-scale population studies have revealed the high prevalence of vitamin D deficiency even in sunshine-rich countries such as India \[[@cit0021]--[@cit0023]\]. Epidemiologic and case-controlled studies have demonstrated that low vitamin D levels are associated with head and neck cancer risk \[[@cit0024], [@cit0025]\]. In the present work a large proportion of study subjects across both groups (76.3% of cases and 68.4% of healthy controls) were found to be deficient in vitamin D, with significantly lower mean levels in cases compared to healthy controls. Orell--Kotikangas *et al*. reported vitamin D insufficiency in 20% and deficiency in 45% of head and neck cancer cases. \[[@cit0026]\] Afzal *et al*. \[[@cit0027]\] reported finding that a low plasma vitamin D level was associated with increased risk of tobacco-related cancer including head and neck cancer. Low levels of vitamin D have also been associated with an increased risk of colon and rectal cancer \[[@cit0028], [@cit0029]\], breast cancer \[[@cit0030]\], ovarian cancer \[[@cit0031]\], prostate cancer \[[@cit0032]\] and esophageal cancers \[[@cit0033]\].

Ameliorating the symptoms of disease per se and toxicities associated either with chemotherapy or radiation in a palliative setting is of paramount importance. Visacri *et al*. found in their cohort study that low performance status and tumor progression (T4 stage disease) predict worse QOL and special attention should be given to these patients \[[@cit0034]\]. The beneficial effect of vitamin D has been supported in a review by Feldman *et al*. \[[@cit0019]\] In the present work in advanced cancer patients receiving chemoradiation, in all cases the vitamin D scores were deficient during the pre-supplementation stage. After completion of therapy, after 3 months there was substantial improvement in vitamin D scores of both groups, i.e. Group I without supplementation and Group II with vitamin D supplementation (increase of 0.89 ±0.90 vs. 1.52 ±0.51 in vitamin D score respectively; *p* = 0.032). A plausible explanation may be that adjuvant therapy resulted in clinical improvement and hence increased oral intake. A report by Ying Gao *et al*. \[[@cit0035]\] supports this observation that metabolism of 25-hydroxy vitamin D is not changed by chemotherapy (cisplatin-based) though the levels of 1,25-hydroxy vitamin D are significantly affected.

So far, there is a lack of data on the correlation of beneficial effects of vitamin D with adverse effects during chemotherapy. In the present work three different objective scales were used to assess the impact of vitamin D supplementation on the most observable problems in oral cancer patients due to chemoradiation-induced toxicity, namely oral mucositis, pain, swallowing performance and overall QOL. OMS showed improvement in all nine parameters with significant improvement in erythema (0.24 ±0.44 vs. 1.29 ±0.62; *p* \< 0.001), lichenoid (--0.19 ±0.40 vs 0.08 ±0.41; *p* = 0.029), edema (0.29 ±0.46 vs. 0.96 ±0.55; *p* \< 0.001), ulceration (--0.33 ±0.48 vs 0.46 ±0.59; *p* \< 0.001) and pain scores (0.38 ±0.50 vs 0.88 ±0.61; *p* = 0.005). These differences may be attributed to the effect of vitamin D in differentiation and epithelization of mucosal cells. Similarly, swallowing performance (--0.05 ±0.67 vs 0.71 ±0.46; *p* \< 0.001) and QOL assessed by the Likert scale (0.14 ±0.57 vs 2.08 ±1.28; *p* \< 0.001) also showed significant improvement with vitamin D supplementation. These findings are in line with the observation first made by Fink *et al.* that chemotherapy-induced mucocutaneous toxicity can be treated successfully with vitamin D supplementation \[[@cit0036]\]. However, Kichten *et al*. in a pilot study observed no difference in chemotherapy-related toxicities between patients with normal and abnormal vitamin D levels \[[@cit0037]\]. Exclusively designed clinical trials particularly to evaluate the role of vitamin D supplementation with concomitant chemoradiation in advanced cancer are scarce and few. Radiation-induced mucocutaneous problems such as mucositis, hyposalivation, infections, osteonecrosis, etc, are common problems of direct irradiation in oral cancer patients \[[@cit0038]\]. Delanion *et al.* noted a decrease in chronic radiation-induced fibrosis combining radiation treatment of head and neck cancer with vitamin D/E and pentoxifylline \[[@cit0039]\]. Borek reported that antioxidant supplementation during radiotherapy not only prevents tissue damage but also prevents side effects of radiation therapy, thus improving QOL \[[@cit0040]\]. A recent review in the Journal of National Cancer Institute stated that improving treatment tolerance with antioxidants will enable the patient to complete the full chemotherapy regimen and it would be unethical to disregard the potential benefits of antioxidants in improving patients' ability to tolerate treatments \[[@cit0041]\]. This inference, well supported by our results, holds much importance in advanced cancer where improving QOL is a primary objective.

VDR is known to influence differentiation, aggressiveness and apoptosis of tumors. \[[@cit0019]\]. For hormonal receptor immunohistochemistry studies, a semi-quantitative scoring system such as the IRS improves the predictive and prognostic capabilities compared to their qualitative assessment counterparts \[[@cit0042]\]. In the present study neoplastic oral tissue showed increased VDR expression compared to normal oral mucosa, though the difference was not statistically significant. When correlated with AJCC anatomic stage/prognostic groups, there was a significant decrease in IRS across the stages, indicating the loss of VDR expression with increasing malignant progression. There are very few studies on VDR expression in oral neoplastic tissue in *in vivo* and *ex vivo* settings \[[@cit0043]\]. Published papers hypothesize that calcitriol enhances VDR expression at gene and protein levels *in vitro* in renal and various non-renal tissues in the body, including the colon \[[@cit0044], [@cit0045]\], breast \[[@cit0046], [@cit0047]\] and prostrate \[[@cit0048]\]. Moreover, it is thought that inflammatory peptides/cytokines expressed by tumor-infiltrating leukocytes and oral premalignant/ tumor cells also up-regulate VDR expression in adjacent cells \[[@cit0049]\].

This clinical report has a few limitations of its own. Parameters studied in the three questionnaires such as the pain response are likely to be affected by patient-related variables such as level of education and self-medication. The results observed in the present study of the effect of vitamin D supplementation on quality of life in advanced oral cancer still needs a well designed randomized trial with a long follow-up to generate a better level of evidence.

In summary, the above results demonstrate that vitamin D insufficiency and deficiency are prevalent in patients with oral neoplastic lesions *a priori* at diagnosis. Because vitamin D deficiency may expose the patients to increased risk of treatment-related morbidity, close attention should be paid to correction of nutritional deficits and especially vitamin D deficiency before treatment, especially in a palliative setting. VDR expression is increased in premalignant lesions and oral cancer.
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